Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Light Switch Added to Oligomers Improves Precision of Gene-Blocking Studies

By LabMedica International staff writers
Posted on 23 May 2012
Scientists collaborating with a company that synthesizes antisense oligomers have tested a new Ultraviolet (UV) light-activated on-off switch linked to these molecules. More...
Based on initial testing, the enhanced oligomers promise to deliver detailed insights from studies in fields such as developmental biology and neuroscience.

The team described the advancement in a paper published May 1, 2012, in the journal Development. Philip Washbourne, professor of biology at the Institute of Neuroscience of the University of Oregon (Eugene, USA), says the paper is a proof-of-concept on an idea he discussed with scientists at Gene Tools LLC (Philomath, OR, USA), which produces “Morpholino” oligonucleotides, a form of synthetic short-chain antisense (or sense) oligomers used to block gene function by RNA-binding.

Biologists have been using morpholinos in zebrafish and other model organisms to study development, but the molecules remained in the "on" (active) state. Gene Tools introduced a light-sensitive linker, allowing researchers to control the photo-morpholinos temporally and spatially — even leaving one "on" in one cell and "off" in an adjacent cell — with a pinpoint UV laser beam.

University of Oregon researchers in Westbourne’s lab, led by research associate Alexandra Tallafuss, were challenged to give the new molecules a test run in zebrafish. "Now we can turn them on and off," Prof. Washbourne said, "you can insert them and then manipulate them to learn just when a gene is important, and we learned two things right away." Researchers have known that if the "no tail" gene is blocked in development, zebrafish fail to grow tails. With the new photo-cleavable morpholinos, they discovered that the no-tail gene does not need to produce protein for tail formation until about 10 hours, or very late, into an embryo's development. Secondly, the researchers looked at the gene sox10 that is vital in the formation of neural crest cells. "Again, we found that sox10 is not needed as early in development as theorized," Prof. Washbourne said.

"These light-sensitive molecules significantly expand the power and precision of molecular genetic studies in zebra fish," said Robert Riddle, a program director at the National Institute of Neurological Disorders and Stroke (NINDS); "Researchers from many fields will be able to use these tools to explore the function of different genes in embryonic regions, specific cell types, and at precise times in an animal's lifespan."

Related Links:
Institute of Neuroscience, University of Oregon
Gene Tools LLC



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Laboratory Software
ArtelWare
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.